Pharmacies Increase Digital Visibility to Offer Affordable Medications amid Coronavirus Pandemic

Telehealth services and mental health apps are storming the acute agitation and aggression treatment market during the ongoing coronavirus pandemic. Since increasing number of individuals are unable to afford treatment or medications, affordable telehealth services and mental health apps are helping to reduce anxiety among individuals.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111790

Online pharmacies in the acute agitation and aggression treatment market are increasing their visibility digitally to help individuals compare the prices of medications. Manufacturers are maintaining optimum inventory levels to ensure a continuous supply of therapeutics. An increasing number of pharmaceutical companies are providing coupons and price reduction promo codes to help individuals purchase medications. Even insurance providers are refilling the prescription of patients well before the refill date in order to improve patient quality of life.

Research Investment Helps in Development of Well-tolerated Antidepressants

Like all medications, even antidepressants are associated with side effects such as headache, nausea, and insomnia in many cases. Hence, companies in the acute agitation and aggression treatment market are continuously investing in R&D to develop improved formulations of antidepressants. As such, antidepressants such as serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), and atypical antidepressants are well-tolerated in individuals.

In order to reduce reliance on antidepressants, healthcare providers are increasing emphasis on behavioral approaches including lifestyle changes, brain stimulation therapies, and integrative medicines in order to improve patient outcomes. There is a growing awareness about different forms of psychotherapy that are helping patients suffering from depression. Cognitive behavioral therapy (CBT), diet changes, and family therapy are being publicized to improve patient quality of life.

Benzodiazepines Gain Prominence in Emergency Department for Rapid Treatment of Acute Agitation

The acute agitation and aggression treatment market is predicted to expand at a modest CAGR of 5.1% during the forecast period. Manufacturers are increasing the production of benzodiazepines for the rapid treatment of acute agitation in the emergency department (ED). Benzodiazepines are being known for sedating an undifferentiated patient without obvious delirium or psychiatric disease. However, benzodiazepines carry the risk of creating a paradoxical reaction in patients, especially the elderly and young population. As such, it has been found that benzodiazepines are well-tolerated and adverse reactions are rare.

Healthcare providers in the acute agitation and aggression treatment market are increasing awareness that benzodiazepines carry the risk for respiratory depression and hence must be avoided for patients who have ingested other depressant medications.

Lorazepam Being Publicized for Effective Treatment of Acutely Agitated Patients

The acute agitation and aggression treatment market is projected to cross the value of US$ 7.09 Bn by 2031. Acute agitation is a frequent occurrence in both inpatient and outpatient psychiatric settings. This is acting as a key driver for market growth. Manufacturers in the acute agitation and aggression treatment market are increasing their production for Lorazepam, which is a type of benzodiazepine that is being extensively used for the management of acute agitation.

Lorazepam is being publicized as a clinically effective means of treating acutely agitated patients. This medication is being frequently used as the sedative and anxiolytic of choice in inpatient settings due to its rapid onset of action when administered intravenously.

acute agitation and aggression treatment market segmentation

Analysts’ Viewpoint

Several brick and mortar pharmacies have started offering telemedicine services to help patients stock their medications during the ongoing COVID-19 pandemic. Apart from medications, healthcare providers in the acute agitation and aggression treatment market are providing non-pharmacologic de-escalation techniques including verbal de-escalation, combined with re-orientation and successive attempts at a therapeutic alliance. Sedation related adverse events, owing to medications should be overcome with increased research in well-tolerated therapeutic formulations. Manufacturers are producing Olanzapine for the treatment of agitation meant for intravenous administration. Midazolam, on the other hand, is being made available for intranasal and oral route of administration in acutely agitated patients, especially in EDs.

Acute Agitation and Aggression Treatment Market: Overview

This report analyzes the current scenario and future prospects of the global acute agitation and aggression treatment market. Rise in burden of mental illnesses and increase in agitation in patients are projected to boost the growth of the global acute agitation and aggression treatment market.

The report includes an elaborate executive summary, which provides a snapshot of various segments of the global acute agitation and aggression treatment market. It also provides information and data analysis of the acute agitation and aggression treatment market about segments based on treatment approach, route of administration, indication, end-user, and region.

The overview section of the report provides a detailed qualitative analysis of drivers, restraints, and opportunities that affect the global acute agitation and aggression treatment market

The report includes company profiles, which provide information about their business, product portfolios, and competitive landscape in the global acute agitation and aggression treatment market

The report on the acute agitation and aggression treatment market offers market attractiveness analysis of regions and segments

The last section of the report comprises quantitative and qualitative analyses on market share/position of key players operating in the global acute agitation and aggression treatment market. It analyzes key competitive strategies adopted by major industry players, thereby presenting a thorough understanding of the competitive scenario in the global acute agitation and aggression treatment market.

Acute Agitation and Aggression Treatment Market: Key Segments

In terms of treatment approach, the global acute agitation and aggression treatment market has been classified into behavioral approaches, environmental interventions, and pharmacologic approaches (drugs). The pharmacologic approaches (drugs) segment has been split into lorazepam, chlorpromazine, quetiapine, droperidol, olanzapine, ziprasidone, and others. The pharmacologic approaches (drugs) segment accounted for major share of the market in 2020 and the trend is anticipated to continue during the forecast period. Benefits of drugs such as ease of administration, rapid onset of action, and sufficient duration of effect are expected to boost the demand for pharmacologic approach for agitation and aggression treatment, which in turn is likely to augment the segment.

Based on route of administration, the global acute agitation and aggression treatment market has been categorized into oral, intramuscular, and others. The oral segment dominated the market in 2020. Growth of the segment can be attributed to the recommended usage of agitation treatment drugs in oral form.

In terms of indication, the global acute agitation and aggression treatment market has been segregated into schizophrenia, dementia, bipolar disorder, depression, drug-induced agitation & aggression, alcohol withdrawal, and others. Rise in prevalence of schizophrenia is projected to drive the schizophrenia segment.

Based on end-user, the global acute agitation and aggression treatment market has been divided into hospitals & ambulatory surgical centers, psychiatric care facilities, and others. The hospitals & ambulatory surgical centers segment accounted for major share of the market. Rise in occurrence of agitation in hospitalized patients is anticipated to propel the segment.

Market size and forecast for each of these segments have been provided from 2017 to 2031. The CAGR of respective segments has also been provided from 2021 to 2031, considering 2020 as the base year.

Acute Agitation and Aggression Treatment Market: Regional Outlook

In terms of region, the global acute agitation and aggression treatment market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, Spain, Italy, France, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, and Rest of Middle East & Africa). Each region considered in the market has been divided into countries/sub-regions.

The acute agitation and aggression treatment market report provides size and forecast for each region and country/sub-region from 2017 to 2031. The CAGR for each of these regions and countries has also been provided for the forecast period from 2021 to 2031. The acute agitation and aggression treatment market study also covers the competitive scenario in these regions.

Companies Covered in Acute Agitation and Aggression Treatment Market Report

Key players in the global acute agitation and aggression treatment market have been profiled based on attributes such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies

Major companies profiled in the acute agitation and aggression treatment market report are

• Eli Lilly and Company
• Pfizer, Inc.
• GlaxoSmithKline
• Otsuka Holdings Co., Ltd.
• Johnson & Johnson
• Teva Pharmaceutical Industries Ltd
• Amneal Pharmaceuticals LLC
• H. Lundbeck A/S., among others.

Key Questions Answered in Acute Agitation and Aggression Treatment Market Report

• What is the revenue forecast for the global acute agitation and aggression treatment market in terms of revenue for the period 2021–2031?
• How would various dynamics such as drivers, restraints, opportunities, and trends affect the market?
• What is the market size and estimation for the acute agitation and aggression treatment market across regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa?
• Which regional market is poised to expand at a significant CAGR during the forecast period?
• Which product segment is projected to generate considerable revenue in 2031 and which application segment will register the fastest CAGR during the forecast period?

Acute Agitation and Aggression Treatment Market – Segmentation

Treatment Approach

• Behavioral Approaches
• Environmental Interventions
• Pharmacologic Approaches (Drugs)
• Lorazepam
• Chlorpromazine
• Quetiapine
• Droperidol
• Olanzapine
• Ziprasidone
• Others

Indication

• Schizophrenia
• Dementia
• Bipolar Disorder
• Depression
• Drug-induced Agitation & Aggression
• Alcohol Withdrawal
• Others

Route of Administration

• Oral
• Intramuscular
• Others

End-user

• Health Care Providers
• Psychiatric Care Facilities
• Others

Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111790/2900